Physician profile
Smitha John
NPI 1275050684
$6,704.86
in general payments reported to CMS, 2019-2025
34 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,203 · 2022: $1,391 · 2023: $1,414 · 2024: $1,453 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,103 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,102.66 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,076.97 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $771.67 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $710.98 | 2021-2025 | Tezspire, Farxiga, Airsupra |
| Abbvie INC. | $682.62 | 2021-2025 | |
| Novo Nordisk INC | $492.66 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $483.42 | 2021-2024 | Jardiance |
| Exact Sciences Corporation | $291.79 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $290.43 | 2021-2024 | Korlym |
| Janssen Pharmaceuticals, INC | $236.78 | 2021-2024 | Xarelto |
| Lilly USA, LLC | $192.65 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $189.28 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $178.48 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $165.65 | 2021-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $145.37 | 2023 | Eliquis, Camzyos |
| Abbott Laboratories | $129.25 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $94.37 | 2021-2023 | Isturisa, Signifor Lar |
| Sanofi-Aventis U.S. LLC | $79.24 | 2022 | |
| Amgen INC. | $65.19 | 2023-2025 | Repatha, Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $56.00 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $49.98 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $33.37 | 2022 | |
| Boston Scientific Corporation | $30.79 | 2022 | |
| Ibsa Pharma INC. | $29.71 | 2021 | |
| Medicomp INC | $29.37 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $27.95 | 2025 | Neffy |
| Nestle Healthcare Nutrition INC. | $27.41 | 2021-2022 | |
| Mylan Specialty L.P. | $23.42 | 2023 | Yupelri |
| Medtronic, INC. | $20.75 | 2023 | Minimed 770g |
| Dexcom, INC. | $20.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.22 | 2022 | |
| Genentech USA, INC. | $17.18 | 2021 | |
| Eusa Pharma (US) LLC | $15.80 | 2022 | |
| Therapeuticsmd, INC. | $15.42 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smitha John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.